NCT05790460: TESTING

Telehealth Based Synchronous Navigation to Improve Molecularly-Informed Care for Patients With Lung Cancer

Terminated NA Results posted Last updated 22 April 2025

What this trial tests

NA trial testing Telehealth in Non-small Cell Lung Cancer in 55 participants. Terminated before completion.

Timeline

8 May 2023

Primary endpoint
11 January 2024

9 November 2024

Quick facts

Lead sponsor	Abramson Cancer Center at Penn Medicine
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	health services research
Enrollment	55
Start date	8 May 2023
Primary completion	11 January 2024
Estimated completion	9 November 2024
Sites	1 location across United States

Drugs / interventions tested

• Telehealth

Conditions studied

• Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →

Sponsor

Abramson Cancer Center at Penn Medicine — full company profile →

Who can join

18 and older, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Molecularly-informed Treatment Recommendations Primary · Measured up to 12 weeks from randomization

Receipt of a molecularly-informed treatment recommendation for patients with metastatic NSq NSCLC at the time of the patient's initial oncology visit.

Group	Value	95% CI
Telehealth	2
Usual Care	2

Rate of Telehealth Visit Completion Secondary · Measured up to 3 weeks from randomization

Telehealth visit completion defined as successful completion of a telehealth visit prior to biopsy

Group	Value	95% CI
Telehealth	25

Rate of Completion of Comprehensive Molecular Testing (Tissue and/or Plasma Testing) Prior to Initiation of First Line Therapy Secondary · Measured up to 12 weeks from randomization

Rate of completion of comprehensive molecular testing (tissue and/or plasma testing) prior to initiation of first line therapy

Group	Value	95% CI
Telehealth	26
Usual Care	12

Identification of One or More Targetable Mutations Secondary · Measured up to 12 weeks from randomization

Identification of one or more targetable mutations

Group	Value	95% CI
Telehealth	2
Usual Care	2

Timeliness of Molecularly-informed Treatment Recommendation Secondary · Measured up to 12 weeks from randomization

Time from randomization to recommendation of a molecularly-informed treatment, as documented in the EMR

Group	Value	95% CI
Telehealth	17.6	16 – 18
Usual Care	38.5	27.5 – 43

Overall Survival Secondary · Measured up to 1 year from the time of randomization to death from any cause

Overall survival

Group	Value	95% CI
Telehealth	5
Usual Care	4
Telehealth	1
Usual Care	2

Proportion of Patients With Diagnosis Other Than Metastatic Nonsquamous NSCLC (Telehealth Arm Only) Secondary · Measured at 12 weeks from randomization

Proportion of patients with diagnosis other than metastatic nonsquamous NSCLC (Telehealth arm only)

Group	Value	95% CI
Telehealth	21

Time From Randomization to Treatment Initiation Secondary · Measured at 12 weeks from randomization

Time from randomization to treatment initiation

Group	Value	95% CI
Telehealth	27.6	23 – 35
Usual Care	50.3	38 – 67

Sponsor's own description

The goal of this trial is to design and test a telehealth nurse navigation intervention for patients with suspected locally advanced/metastatic NSCLC to improve timely molecularly-informed treatment recommendations through early integration of concurrent molecular testing.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

1. Patient Navigation in Cancer Treatment: A Systematic Review.
   Chen M, Wu VS, Falk D, Cheatham C, et al · · 2024 · cited 72× · PMID 38581470 · DOI 10.1007/s11912-024-01514-9
2. Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine.
   Bao Y, Zhang D, Guo H, Ma W. · · 2024 · cited 62× · PMID 38308498 · DOI 10.1111/cas.16097
3. University of Pennsylvania Telehealth Research Center of Excellence.
   Wainwright JV, Aggarwal C, Beucker S, Dougherty DW, et al · · 2024 · cited 1× · PMID 38924794 · DOI 10.1093/jncimonographs/lgae011